Clonal Brown Fat Progenitor Derivation for Uniform BAT Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved methods to screen and differentiate pluripotent stem cell-derived cells for potential of differentiation into desired cell types, particularly brown adipose tissue (BAT) cells, which can effectively treat metabolic disorders such as diabetes, obesity, and coronary disease, and to generate progenitor cell types that display uniform differentiated states and site-specific gene expression patterns.
Innovation Solution
The method involves isolating and expanding clonal embryonic progenitor cell lines from pluripotent stem cells in the presence of noggin, an inactivator of the TGF-beta family of growth factors, to create cell lines that express specific markers like UCP1, C19orf80, and adiponectin, and do not express COX7A1, allowing them to differentiate into site-specific BAT cells capable of secreting beneficial adipokines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional differentiation methods are used for pluripotent stem cells, then cell differentiation occurs, but the differentiation is non-uniform and lacks site-specific gene expression patterns
Solution Approach 1:
The patent applies parameter changes by modifying the chemical composition and concentration of differentiation media. Specific factors such as BMP4, dexamethasone, and insulin-like growth factor 1 are used at controlled concentrations to guide uniform differentiation into brown fat cells with site-specific gene expression patterns.
Solution Approach 2:
The patent uses intermediary substances including growth factors and signaling molecules that mediate the differentiation process. These intermediaries transmit signals from the differentiation medium to the pluripotent stem cells, enabling controlled and uniform differentiation without direct manipulation of the cells themselves.
2Reliability
If screening methods are applied to identify cells with desired differentiation potential, then cell quality improves, but screening time and resource requirements increase
Solution Approach 1:
The patent implements preliminary action by pre-differentiating pluripotent stem cells under controlled conditions before transplantation. This preliminary differentiation step ensures that only cells with the desired brown fat cell characteristics are selected, improving reliability while reducing the need for extensive post-differentiation screening.
Solution Approach 2:
The patent replaces mechanical or manual screening methods with molecular markers and gene expression analysis. By using specific markers such as UCP1 and C19orf80 expression levels, the system automatically identifies cells with desired differentiation potential, reducing time and resource requirements compared to manual screening.
3Reliability
If pluripotent stem cells are differentiated into brown fat cells, then therapeutic effect increases, but cell heterogeneity decreases
Solution Approach 1:
The patent applies local quality by inducing site-specific gene expression patterns in the differentiated brown fat cells. Specific genes such as UCP1, C19orf80, and adiponectin are upregulated in a controlled manner, creating cells with localized functional characteristics that enhance therapeutic effectiveness while maintaining operational simplicity.
Data Source
AI summary
Aspects of the present invention include methods and compositions related to the production and use of pluripotent stem cell-derived clonal embryonic progenitor cell types useful in the generation of cellular components of brown adipocyte tissue for research and therapy relating to applications in obesity, diabetes, and cardiovascular disease.